T315I clone selection in a Ph+ all patient under low‐dose ponatinib maintenance

We report here the clinical course of a Ph+ ALL patient who was treated with ponatinib 15 mg/day, as maintenance therapy, and developed a BCR‐ABL T315I mutation leading to ALL relapse. This clonal evolution was reversed, without adverse effects, by increasing ponatinib to 45 mg/day. To our knowledge...

Descripción completa

Detalles Bibliográficos
Autores principales: Noetzli, Jasmine, Gavillet, Mathilde, Masouridi‐Levrat, Stavroula, Duchosal, Michel, Spertini, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538043/
https://www.ncbi.nlm.nih.gov/pubmed/28781850
http://dx.doi.org/10.1002/ccr3.1032
_version_ 1783254291406913536
author Noetzli, Jasmine
Gavillet, Mathilde
Masouridi‐Levrat, Stavroula
Duchosal, Michel
Spertini, Olivier
author_facet Noetzli, Jasmine
Gavillet, Mathilde
Masouridi‐Levrat, Stavroula
Duchosal, Michel
Spertini, Olivier
author_sort Noetzli, Jasmine
collection PubMed
description We report here the clinical course of a Ph+ ALL patient who was treated with ponatinib 15 mg/day, as maintenance therapy, and developed a BCR‐ABL T315I mutation leading to ALL relapse. This clonal evolution was reversed, without adverse effects, by increasing ponatinib to 45 mg/day. To our knowledge, we have been confronted with the first clinical case of a T315I clonal selection of ALL caused by subeffective therapeutic level of the drug. This single patient experience highlights the risk of T315I clone selection in Ph+ ALL treated with reduced dose ponatinib.
format Online
Article
Text
id pubmed-5538043
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-55380432017-08-04 T315I clone selection in a Ph+ all patient under low‐dose ponatinib maintenance Noetzli, Jasmine Gavillet, Mathilde Masouridi‐Levrat, Stavroula Duchosal, Michel Spertini, Olivier Clin Case Rep Case Reports We report here the clinical course of a Ph+ ALL patient who was treated with ponatinib 15 mg/day, as maintenance therapy, and developed a BCR‐ABL T315I mutation leading to ALL relapse. This clonal evolution was reversed, without adverse effects, by increasing ponatinib to 45 mg/day. To our knowledge, we have been confronted with the first clinical case of a T315I clonal selection of ALL caused by subeffective therapeutic level of the drug. This single patient experience highlights the risk of T315I clone selection in Ph+ ALL treated with reduced dose ponatinib. John Wiley and Sons Inc. 2017-07-03 /pmc/articles/PMC5538043/ /pubmed/28781850 http://dx.doi.org/10.1002/ccr3.1032 Text en © 2017 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Noetzli, Jasmine
Gavillet, Mathilde
Masouridi‐Levrat, Stavroula
Duchosal, Michel
Spertini, Olivier
T315I clone selection in a Ph+ all patient under low‐dose ponatinib maintenance
title T315I clone selection in a Ph+ all patient under low‐dose ponatinib maintenance
title_full T315I clone selection in a Ph+ all patient under low‐dose ponatinib maintenance
title_fullStr T315I clone selection in a Ph+ all patient under low‐dose ponatinib maintenance
title_full_unstemmed T315I clone selection in a Ph+ all patient under low‐dose ponatinib maintenance
title_short T315I clone selection in a Ph+ all patient under low‐dose ponatinib maintenance
title_sort t315i clone selection in a ph+ all patient under low‐dose ponatinib maintenance
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538043/
https://www.ncbi.nlm.nih.gov/pubmed/28781850
http://dx.doi.org/10.1002/ccr3.1032
work_keys_str_mv AT noetzlijasmine t315icloneselectioninaphallpatientunderlowdoseponatinibmaintenance
AT gavilletmathilde t315icloneselectioninaphallpatientunderlowdoseponatinibmaintenance
AT masouridilevratstavroula t315icloneselectioninaphallpatientunderlowdoseponatinibmaintenance
AT duchosalmichel t315icloneselectioninaphallpatientunderlowdoseponatinibmaintenance
AT spertiniolivier t315icloneselectioninaphallpatientunderlowdoseponatinibmaintenance

Ejemplares similares